AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04387097 — intervention group
Intervention type: DRUG
Intervention: remifentanil
Description: postoperative drip-infusion of remifentanil
Study NCT04025593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750mg/m2 day 1
Study NCT04025593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750mg/m2 day 1
Study NCT04025593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375mg/m2 day 0
Study NCT04025593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 day 0
Study NCT04025593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50mg/m2 day 1
Study NCT00383474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV
Study NCT00383474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00383474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Given orally
Study NCT04025593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50mg/m2 day 1
Study NCT04025593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 1.4mg/m2, max 2mg day 1
Study NCT04025593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4mg/m2, max 2mg day 1
Study NCT04025593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 60mg/m2, max 100mg day 1-5
Study NCT04025593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60mg/m2, max 100mg day 1-5
Study NCT04025593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 420mg/day qd
Study NCT01779219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iMRI-guided brain tumour biopsy
Description: The PoleStar N20 iMRI system (Medtronic Navigation, Louisville, CO, USA) with a 0.15-T constant magnet was used in all procedures.
Study NCT01779219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic frameless brain tumour biopsy
Description: The entry point, target and optimal biopsy trajectory were defined by the operator before the operation on the basis of the preoperatively obtained high-field MR images with the use of a neuronavigation workstation (Cranial 5, StealthStation Application Software, Medtronic Navigation, Louisville, CO, USA).
Study NCT00534313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Solution, intravenous, monthly, short-term = 24 weeks (6 months)
Study NCT04025593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25mg day1-10
Study NCT04025593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide
Description: 20mg day 1,4,8,11
Study NCT04025593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: decitabine 10mg/m2 day-5 to day-1
Study NCT00971126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib (Nexavar®), thalidomide (Thado®)
Description: Phase I Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and Escalation dose of Thalidomide at dose Level I: 50 mg/day (50mg, p.o., qd); Level II: 100 mg/day (50mg, p.o., bid); Level III: 150 mg/day (100mg/50mg, p.o., bid); Level IV: 200 mg/day (100mg, p.o., bid).~Phase II Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and MTD of Thalidomide at phase I study.
Study NCT02429856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SCORPIO™
Description: subjects randomized at surgery to receive 1 of the 2 specified implants
Study NCT00206544 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: adjunctive placebo daily in oral capsule
Study NCT05440903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Headspace
Description: A smartphone application that provides users with mindfulness and meditation sessions.
Study NCT00534313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution, intravenous, placebo (double dummy), monthly, short-term = 24 weeks (6 months)
Study NCT00725842 — intervention group
Intervention type: BIOLOGICAL
Intervention: Peg-IFN alfa-2b
Description: Peg-IFN alfa-2b administered in accordance with approved labeling
Study NCT00725842 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin administered in accordance with approved labeling
Study NCT02243462 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Forced Air Warmer
Description: A forced air warmer device will be used to pre-warm patients for 10 minutes in holding bay before surgery. Air warming device is an electrically powered control unit, hose, and inflatable blanket. The control unit has an air filter and heater, which warms air entrained from the environment. The hose connects to a blanket.
Study NCT02243462 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No pre-op warming
Description: No forced air warming of the patient prior to being taken in for surgery
Study NCT03841747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Pembrolizumab IV Q3W.
Study NCT03841747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m2 paclitaxel IV on Days 1,8, and 15 of each 28 day cycle.
Study NCT03841747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 paclitaxel IV on Days 1,8, and 15 of each 28 day cycle.
Study NCT04097951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combinations
Description: Montelukast and Bepotastine Combination
Study NCT03002090 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron trained
Description: 1. Ferrous sulfate: 100 mg/day of FeSO4 dosed in 2 capsules taken individually by mouth with breakfast and dinner. Capsules were made with FeSO4 and dextrose. Analysis has shown that each capsule contains 11mg of elemental iron, which is expected to be absorbed at roughly 33% bioavailability.~2. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate.
Study NCT03002090 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron Untrained
Description: 1. Ferrous sulfate: 100 mg/day of FeSO4 dosed in 2 capsules taken individually by mouth with breakfast and dinner. Capsules were made with FeSO4 and dextrose. Analysis has shown that each capsule contains 11mg of elemental iron, which is expected to be absorbed at roughly 33% bioavailability.
Study NCT03002090 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BZKL Trained
Description: 1. BaZhen KeLi capsules: Traditional Chinese herbal supplement composed of: Radix Paeoniae Alba (White peony root), Rhizoma Atractylodis (Atractylodes), Rhizoma Chuanxiong (Chuanxiong), Radix Angelicae Sinensis (Angelica), Radix Codonopsis Pilosula (Codonopsis), Poria cocos (Poria), licorice, and Rehmannia glutinosa Each pill contained 5g of licorice and 10g of all other ingredients. Dosed in 2 capsules taken individually by mouth with breakfast and dinner. Analysis has shown that each capsule contained 0.5mg of elemental iron.~2. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate.
Study NCT03002090 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BZKL Untrained
Description: 1. BaZhen KeLi capsules: Traditional Chinese herbal supplement composed of: Radix Paeoniae Alba (White peony root), Rhizoma Atractylodis (Atractylodes), Rhizoma Chuanxiong (Chuanxiong), Radix Angelicae Sinensis (Angelica), Radix Codonopsis Pilosula (Codonopsis), Poria cocos (Poria), licorice, and Rehmannia glutinosa Each pill contained 5g of licorice and 10g of all other ingredients. Dosed in 2 capsules taken individually by mouth with breakfast and dinner. Analysis has shown that each capsule contained 0.5mg of elemental iron.
Study NCT03002090 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Trained
Description: 1. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate.
Study NCT03002090 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Untrained
Description: No intervention
Study NCT03035474 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Digital Engagement
Description: Patient engagement to improve self-management/medication adherence
Study NCT05440903 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TEDTalk
Description: A smartphone application that provides users with psychoeducational audio recordings from TEDTalk.
Study NCT03035474 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Direct Engagement
Description: Health system engagement to improve local QI programs
Study NCT02081859 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Embryoscope
Description: The embryoscope is a microscope that allows for continuous time-lapse monitoring.
Study NCT02081859 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Criteria
Study NCT03438721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant obesity prevention
Description: Parents will receive education on infant feeding, sleep, and screen time practices just after well-child visits in the first year of life. The education will be provided by a lay health educator. Parents will also receive text messages to reinforce the intervention content
Study NCT03438721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial coaching
Description: Parents randomized to the financial coaching arm will receive basic education on financial topics including budgeting, savings, and managing debt as well as coaching on these topics just after well-child visits in the first year of life. Coaching will be provided by lay health educators trained in financial coaching. Parents will also receive text messages reinforcing the information learned.
Study NCT03444480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosylate
Description: Initial dose plus supplemental doses
Study NCT04160975 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video about safety and effectiveness of adult seasonal flu vaccination
Description: The investigators will show subjects videos of either Black or white male actors providing scripted information on the flu vaccination. The content of the video will be the safety and effectiveness of adult seasonal flu vaccination. The videos contain one of Black or white actors playing the role of either a doctor or a layperson as well as different scripts.
Study NCT00766350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amitriptyline
Description: initial dose 10 mg/day, target dose: 25 mg/day, maximum dose: 75 mg/day, dosage form: tablets, duration: 16 weeks
Study NCT00766350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: initial dose: 50 mg/day, target dose: 100 mg/day, maximum dose: 300 mg/day, dosage form:extended release tablets , duration: 16 weeks
Study NCT02687867 — intervention group
Intervention type: DRUG
Intervention: Dabigatran (Pradaxa)
Description: As prescribed by treating physicians
Study NCT02687867 — intervention group
Intervention type: DRUG
Intervention: Vitamin K antagonist
Description: As prescribed by treating physicians
Study NCT03759808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Intervention
Description: Psychological treatment protocol designed to treat anxiety and avoidance in an adolescent/young adult population. The focus of treatment will be to address cognitive and behavioral factors associated with prolonged symptoms. Cognitive factors that may be addressed include, but are not limited to, catastrophizing, black or white thinking, and false expectations. Behavior factors that may be addressed include, but are not limited to, avoidance, relaxation, and behavioral activation. The psychological intervention is also designed to help reduce psychophysiological arousal associated with anxiety and stress. Participants will also be taught controlled shallow breathing exercises designed to normalize the ratio of sympathetic/parasympathetic activity.
Study NCT01150669 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Samples are analyzed in laboratory studies
Study NCT01854346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social skills group training, KONTAKT
Description: KONTAKT is a manual-based social skills group training for children with high functioning autism spectrum disorder (ASD). The program is based on cognitive behavioral therapy (CBT) principles and knowledge of social cognition. The group treatment includes exercises in social skills as well as discussions of social cognition, social interaction, self-reflection and description of themselves and others. The children are training to make contact, to understand and follow social rules, to become aware of themselves and others, to perceive verbal and nonverbal signals in a communication, to develop problem solving skills and coping strategies to manage conflict and to enhance their self-confidence. Intervention includes 12 (brief intervention) and 24 (long intervention) sessions. Each group consists of 4-8 children/adolescents ant two group leaders. The treatment are conducted in cooperation with both parents and teachers.
Study NCT00420511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: sitagliptin 100 mg once a day
Study NCT00420511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo once a day
Study NCT00420511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: metformin 1000 mg twice a day (bid) by mouth (po)
Study NCT00420511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: metformin 1000 mg twice a day (bid) by mouth (po)
Study NCT01756274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour® NEXT BGMS
Description: Lab professionals tested the BG concentration using Contour® NEXT BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
Study NCT01756274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour® PLUS BGMS
Description: Lab professionals tested the BG concentration using Contour® PLUS BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
Study NCT01756274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour® Next EZ BGMS
Description: Lab professionals tested the BG concentration using Contour® Next EZ BGMS (Blood Glucose Monitoring System). All meter BG results were compared with plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
Study NCT03765593 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy Salivary Gland
Description: A minor salivary gland biopsy will be performed at lower lip, with the minimally invasive technique that is carried out in Rheumatology Unit as a routine procedure for the diagnosis of pSS, from there it will be taken between 2-3 glands for the study. RNAlater®(Ambion, Inc., Texas, United States of America) will be stored in solution for the stabilization and preservation of RNA at -80ºC.
Study NCT04370340 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BabySlide
Description: Application of BabySlide during vacuum-assisted births for perineal protection
Study NCT04171609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: During this daylong expressive writing workshop intervention, the writing instructor coached participants through a series of simple writing exercises. Participation required neither any prior writing experience, nor any desire to become a writer. The practices cultivate natural abilities to express the ideas that define who you are and how you experience your life.
Study NCT01474590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epiduo/Tactuo
Description: topical to the face, once daily in the evening
Study NCT01474590 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vehicle gel
Description: topical to the face, once daily in the evening
Study NCT01474590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxycycline 200mg
Description: oral, 2 capsules once daily in the morning with aglass of water and with food
Study NCT01220544 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haploidentical transplantation with donor NK cells
Description: Pat received a myeloablative conditioning regimen with 12 Gy total-body irradiation in six single doses from day -11 to day -9, thiotepa (5mg/kg/d) on days -8 and -7, fludarabine (40mg/m2/d) from day -6 to day -3, and OKT-3 (5mg/d) from day -5 to day +3. The stem cell graft was aimed to contain > 8 x 10e6 CD34+ cells/kg and \< 5 x 10e4 CD3+ cells/kg. A minimum of 1 x 10e7 CD56+CD3- NK cells/kg will be transferred on days +2.
Study NCT03129425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReNACE Psychoeducational Intervention
Description: 9 sessions in groups of 15-20 people at most so as to promote reflection and facilitate the interchange of opinions between participants about issues of interest from their day to day experience of coping with Parkinson's disease.
Study NCT03129425 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: General Educational Program
Description: 5 sessions in groups of 15-20 people
Study NCT01533298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CombiflexOmega peri
Description: intravenously over 3 days infusion
Study NCT01533298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SmofKabiven peripheral
Description: intravenously over 3 days infusion
Study NCT02342054 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI-TRUS fusion guided Single Frac HDR
Study NCT02993991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat
Description: Mocetinostat (MGCD0103) is a potent small molecule HDAC inhibitor that targets human HDAC isoforms. It is an orally bioavailable, second generation benzamide inhibitor of HDAC 1, 2, 3 and 11 with broad spectrum antitumor activity in vitro and in vivo.
Study NCT01474590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: oral, 0.5mg/kg/day for a period of four weeks, adjusted to 1 mg/kg/day for the four following months.
Study NCT03529747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online self-help
Description: As detailed in experimental arm description.
Study NCT01958957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgolides Meglumine Injection
Description: 25mg, intravenous drip, once a day. Number of Cycles: 14 days.
Study NCT00456690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional recommendations
Description: Nutritional status assessment including complete endocrine and lipid laboratory profile and after one year of nutritional follow up a secondary assessment will be done
Study NCT02993991 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against human PD-L1. It is selective for recombinant PD-L1 and blocks the binding of recombinant PD-L1 to the PD-1 and CD80 receptors.
Study NCT04178733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3493269 - SC
Description: Administered SC
Study NCT04178733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - SC
Description: Administered SC
Study NCT04178733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3493269 - IV
Description: Administered IV
Study NCT00510653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: 600 mg by mouth daily for 6 Weeks
Study NCT03330392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AGP
Description: take two tablets per day (500 mg/day) for 8 weeks
Study NCT03330392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: take two tablets per day (500 mg/day) for 8 weeks
Study NCT00254579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: 15 mg/kg Q12W dosing regimen
Study NCT02174588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam + propofol
Description: Midazolam and propofol are used for sedation drug. Balanced propofol sedation (BPS) refers to the administration of an opiate, a benzodiazepine, and propofol.
Study NCT02174588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol are used for sedation drug